Motofen (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing serotonergic 5‑HT2 and 5‑HT3 receptors as well as histamine H1 receptors. This results in higher levels of norepinephrine and serotonin, producing an antidepressant effect.

The appropriate dose of Motofen is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber should evaluate the potential benefits against possible risks to the fetus or infant before initiating therapy. Breastfeeding mothers should discuss alternatives with their healthcare provider.

To order Motofen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Motofen (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonergic receptors. This mechanism can lead to distinct side‑effect profiles, such as higher sedation and appetite stimulation, which may be advantageous or disadvantageous depending on patient needs.

Motofen should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain potency and stability.

Motofen is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include agranulocytosis, severe neutropenia, hepatotoxicity, seizures, hyponatremia, and the emergence or worsening of suicidal thoughts. Patients should be monitored regularly for these rare but potentially life‑threatening events.

Motofen is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients. It should also be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with severe hepatic impairment without appropriate dose adjustment.